Gallium-68-labeled affibody molecule for PET Imaging of PDGFRβ Expression in Vivo

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 3957-3964

  Strand, Joanna ^a   Varasteh, Zohreh ^b   Eriksson, Olof ^b   Abrahmsen, Lars ^c   Orlova, Anna ^b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KDev Oncology Karolinska Institute Science Park   (Sweden)

Author keywords

Affibody molecule; DPTA; Gallium 68; PDGFR beta; PET

Indexed keywords

DOTA Z09591 GA 68; DOTA Z09591 IN 111; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; GALLIUM; INDIUM; MONOCLONAL ANTIBODY; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG TARGETING; ELECTROSPRAY; FEMALE; GLIOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; SCID MOUSE; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GALLIUM RADIOISOTOPES; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MULTIMODAL IMAGING; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927630924     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500284t     Document Type: Article

References (57)

1. Fredriksson, L.; Li, H.; Eriksson, U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15, 197-204.
2. Heldin, C. H.; Westermark, B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990, 1, 555-566.
3. Robson, M. C.; Phillips, L. G.; Thomason, A.; Robson, L. E.; Pierce, G. F. Plateletderived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992, 339, 23-25.
4. Rodt, S. Å.; Åhlen, K.; Berg, A.; Rubin, K.; Reed, R. K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 1996, 495, 193-200.
5. Heldin, C. H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signaling 2013, 11, 97.
6. Heldin, C. H. Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. J. Neuroimmune Pharmacol. 2014, 9, 69-79.
7. Ostendorf, T.; Eitner, F.; Floege, J. The PDGF family in renal fibrosis. Pediatr. Nephrol. 2012, 27, 1041-1050.
8. Ogawa, S.; Ochi, T.; Shimada, H.; Inagaki, K.; Fujita, I.; Nii, A.; Moffat, M. A.; Katragadda, M.; Violand, B. N.; Arch, R. H.; et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol. Res. 2010, 40, 1128-1141.
9. Sano, H.; Sudo, T.; Yokode, M.; Murayama, T.; Kataoka, H.; Takakura, N.; Nishikawa, S.; Nishikawa, S. I.; Kita, T. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 2001, 103, 2955-2960.
10. Tamborini, E.; Miselli, F.; Negri, T.; Lagonigro, M. S.; Staurengo, S.; Dagrada, G. P.; Stacchiotti, S.; Pastore, E.; Gronchi, A.; Perrone, F. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR)B, PDGFRA, and KIT receptors in chordomas. Clin. Cancer Res. 2006, 12, 6920-6928.
11. Yang, J.; Liu, X.; Nyland, S. B.; Zhang, R.; Ryland, L. K.; Broeg, K.; Baab, K. T.; Jarbadan, N. R.; Irby, R.; Loughran, T. P. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010, 115, 51-60.
12. Uehara, H.; Kim, S. J.; Karashima, T.; Shepherd, D. L.; Fan, D.; Tsan, R.; Killion, J. J.; Logothetis, C.; Mathew, P.; Fidler, I. J. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 2003, 95, 458-470.
13. Ehnman, M.; Ostman, A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin. Investig. Drugs 2014, 23, 211-226.
14. Paulsson, J.; Sjoblom, T.; Micke, P.; Ponten, F.; Landberg, G.; Heldin, C. H.; Bergh, J.; Brennan, D. J.; Jirstrom, K.; Ostman, A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175, 334-341.
15. Hagglof, C.; Hammarsten, P.; Josefsson, A. Stromal DGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One 2010, 5, e10747.8.
16. Board, R.; Jayson, G. C. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist. Update 2005, 8, 75-83.
17. Jayson, G. C.; Parker, G. J.; Mullamitha, S.; Valle, J. W.; Saunders, M.; Broughton, L.; Lawrance, J.; Carrington, B.; Roberts, C.; Issa, B. Blockade of plateletderived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 2005, 23, 973-981.
18. Shen, J.; Vil, M. D.; Prewett, M.; Damoci, C.; Zhang, H.; Li, H.; Jimenez, X.; Deevi, D. S.; Iacolina, M.; Kayas, A. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 2009, 11, 594-604.
19. Stacchiotti, S.; Longhi, A.; Ferraresi, V.; Grignani, G.; Comandone, A.; Stupp, R.; Bertuzzi, A.; Tamborini, E.; Pilotti, S.; Messina, A. Phase II study of imatinib in advanced chordoma. J. Clin. Oncol. 2012, 30, 914-920.
20. Bedard, P. L.; Hansen, A. R.; Ratain, M. J.; Siu, L. L. Tumour heterogeneity in the clinic. Nature 2013, 501, 355-364.
21. Tolmachev, V.; Stone-Elander, S.; Orlova, A. Radiolabeled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010, 11, 992-1000.
22. Kil, K. E.; Ding, Y. S.; Lin, K. S.; Alexoff, D.; Kim, S. W.; Shea, C.; Xu, Y.; Muench, L.; Fowler, J. S. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl. Med. Biol. 2007, 34, 153-163.
23. Altai, M.; Orlova, A.; Tolmachev, V. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. Curr. Pharm. Des. 2014, 20, 2275-2292.
24. Kastin, A. J.; Akerstrom, V.; Hackler, L.; Pan, W. Different mechanisms influencing permeation of PDGF-AA and PDGF-BB across the blood-brain barrier. J. Neurochem. 2003, 87, 7-12.
25. Askoxylakis, V.; Marr, A.; Altmann, A.; Markert, A.; Mier, W.; Debus, J.; Huber, P. E.; Haberkorn, U. Peptide-based targeting of the platelet-derived growth factor receptor beta. Mol. Imaging Biol. 2013, 15, 212-221.
26. Marr, A.; Nissen, F.; Maisch, D.; Altmann, A.; Rana, S.; Debus, J.; Huber, P. E.; Haberkorn, U.; Askoxylakis, V. Peptide arrays for development of PDGFRβ Affine molecules. Mol. Imaging Biol. 2013, 15, 391-400.
27. Nygren, P. A.; Skerra, A. Binding proteins from alternative scaffolds. J. Immunol. Methods 2004, 290, 3-28.
28. Lofblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Stahl, S.; Frejd, F. Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 18, 2670-2680.
29. Tolmachev, V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. Des. 2008, 14, 2999-3019.
30. Orlova, A.; Hofstrom, C.; Strand, J.; Varasteh, Z.; Sandstrom, M.; Andersson, K.; Tolmachev, V.; Graslund, T. [(99m)Tc(CO)(3)] (+)-(HE) (3)-Z (IGF1R: 4551), a new affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur. J. Nucl. Med. Mol. Imaging 2012, 40, 439-449.
31. Orlova, A.; Malm, M.; Rosestedt, M.; Varasteh, Z.; Andersson, K.; Selvaraju, R. K.; Altai, M.; Honarvar, H.; Strand, J.; Stahl, S.; Tolmachev, V.; Lofblom, J. Imaging of HER3-expressing xenografts in mice using a 99mTc(CO) 3-HEHEHE-Z HER3: 08699 affibody molecule. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1450-1459.
32. Baum, R. P.; Prasad, V.; Muller, D.; Schuchardt, C.; Orlova, A.; Wennborg, A.; Tolmachev, V.; Feldwisch, J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J. Nucl. Med. 2010, 51, 892-897.
33. Sorensen, J.; Sandberg, D.; Sandstrom, M.; Wennborg, A.; Feldwisch, J.; Tolmachev, V. Åstrom, G.; Lubberink, M.; Garske-Roman, U.; Carlsson, J.; Lindman, H. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the In-ABY-025 affibody molecule. J. Nucl. Med. 2014, 55, 730-735.
34. Lindborg, M.; Cortez, E. Hoiden-Guthenberg, I.; Gunneriusson, E.; von Hage, E.; Syud, F.; Morrison, M.; Abrahmsen, L.; Herne, N.; Pietras, K.; Frejd, F. Y. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. J. Mol. Biol. 2011, 407, 298-315.
35. Tolmachev, V.; Varasteh, Z. Honarvar, H; Hosseinimehr, S. J.; Eriksson, O.; Jonasson, P.; Frejd, F. Y.; Abrahmsen, L.; Orlova, A. Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J. Nucl. Med. 2014, 55, 294-300.
36. Rahmim, A; Zaidi, H. PET versus SPECT: strengths, limitations and challenges. Nucl. Med. Commun. 2008, 29, 193-207.
37. van Dongen. G A; Visser, G. W.; Lub-de Hooge, M. N.; de Vries, E. G; Perk, L. R Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007, 12, 1379-1389.
38. Tolmachev, V. Stone-Elander, S. Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim. Biophys. Acta 2010, 1800, 487-510.
39. Fani, M.; Andre, J. P.; Maecke, H. R 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol. Imaging 2008, 3, 67-77.
40. 111In via maleimido derivatives of DOTA and NODAGA Bioconjugate Chem. 2013, 24, 1102-1109.
41. Ahlgren, S.; Orlova, A.; Rosik, D.; Sandstrom, M.; Sjoberg, A.; Baastrup, B.; Widmark, O.; Fant, G; Feldwisch, J.; Tolmachev, V. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjugate Chem. 2008, 19, 235-243.
42. Strand, J.; Honarvar, H; Perols, A.; Orlova, A.; Selvaraju, R K.; Karlstrom, A. E.; Tolmachev, V Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts. PLoS One 2013, 8, e70028.
43. Heppeler, A.; Froidevaux, S.; Macke, H.R; Jermann, E.; Behe, M.; Powell, P.; Hennig, M. Radiometal-labelled macrocyclic chelatorderivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor rmediated internal radiotherapy. Chem. - Eur. J. 1999, 5, 1974-81.
44. Ginj, M.; Zhang, H; Eisenwiener, K P.; Wild, D.; Schulz, S.; Rink, H.; Cescato, R.; Reubi, J. C.; Maecke, H. R. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin. Cancer Res. 2008, 14, 2019-27.
45. Decristoforo, C.; Hernandez Gonzalez, I.; Carlsen, J.; Rupprich, M.; Huisman, M.; Virgolini, I.; Wester, H. J.; Haubner, R 68Ga- and 111In labeled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1507-15.
46. Ahlgren, S.; Tolmachev, V Radionuclide molecular imaging using affibody molecules. Curr. Pharm. Biotechnol. 2010, 11, 581-589.
47. Vegt, E.; de Jong, M.; Wetzels, J. F.; Masereeuw, R; Melis, M.; Oyen, W. J.; Gotthardt, M.; Boerman, O. C. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 2010, 51, 1049-1058.
48. Tolmachev, V; Tran, T. A.; Rosik, D.; Sjoberg, A.; Abrahmsen, L.; Orlova, A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J. Nucl. Med. 2012, 53, 953-960.
49. Tolmachev, V.; Friedman, M.; Sandstrom, M.; Eriksson, T. L.; Rosik, D.; Hodik, M.; Stahl, S.; Frejd, F. Y.; Orlova, A. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J. Nucl. Med. 2009, 50, 274-283.
50. Christensen, E. I.; Verroust, P. J. Megalin and cubilin, role in proximal tubule function and during development. Pediatr. Nephrol. 2002, 17, 993-999.
51. Altai, M.; Varasteh, Z.; Andersson, K.; Eek, A.; Boerman, O.; Orlova, A. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer. Biother. Radiopharm. 2013, 28, 187-195.
52. Kramer-Marek, G.; Kiesewetter, D. O.; Martiniova, L.; Jagoda, E.; Lee, S. B.; Capala, J. [18F]FBEM-Z(HER2: 342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1008-1018.
53. Cheng, Z.; De Jesus, O. P.; Namavari, M.; De, A.; Levi, J.; Webster, J. M.; Zhang, R.; Lee, B.; Syud, F. A.; Gambhir, S. S. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J. Nucl. Med. 2008, 49, 804-813.
54. Tolmachev, V.; Mume, E.; Sjoberg, S.; Frejd, F. Y.; Orlova, A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 692-701.
55. Rosik, D.; Thibblin, A.; Antoni, G.; Honarvar, H.; Strand, J.; Selvaraju, R. K.; Altai, M.; Orlova, A.; Eriksson Karlstrom, A.; Tolmachev, V. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. Bioconjugate Chem. 2014, 25, 82-92.
56. Koumarianou, E.; Mikołajczak, R.; Pawlak, D.; Zikos, X.; Bouziotis, P.; Garnuszek, P.; Karczmarczyk, U.; Maurin, M.; Archimandritis, S. C. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Nucl. Med. Biol. 2009, 36, 591-603.
57. Heskamp, S.; Laverman, P.; Rosik, D.; Boschetti, F.; van der Graaf, W. T.; Oyen, W. J.; van Laarhoven, H. W.; Tolmachev, V.; Boerman, O. C. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2: 2395 in a mouse model for ovarian cancer. J. Nucl. Med. 2012, 53, 146-153. dx.doi.org/10.1021/mp500284t